质子泵抑制剂在特发性肺纤维化中的有效性:基于人群的队列研究
该研究利用英国临床实践研究数据链,纳入2003至2016年诊断为特发性肺纤维化(IPF)的患者,采用流行新用户队列设计,按时间条件倾向评分匹配1852对PPI使用者和非使用者。结果显示PPI使用与全因死亡(HR 1.07,95%CI 0.94-1.22)、呼吸相关死亡(HR 1.10,95%CI 0.94-1.28)及呼吸相关住院(HR 1.00,95%CI 0.86-1.16)均无显著关联。结论提示PPI可能并不像某些研究和指南条件性推荐的那样对IPF有益。
要点
- PPI使用与IPF患者全因死亡风险无显著降低相关(HR 1.07)。
- PPI使用与呼吸相关死亡和住院风险也无显著关联。
- 研究设计避免了既往研究中的时间相关偏倚,结果更可靠。
核心结论
- 在真实临床实践中,PPI使用与IPF患者全因死亡、呼吸相关死亡及呼吸相关住院风险降低无关。
- PPI可能并不像某些研究和治疗指南条件性推荐的那样对IPF有益。
研究设计与样本
- 基于英国临床实践研究数据链(CPRD)的人群队列研究,纳入2003至2016年诊断为IPF的患者。
- 采用流行新用户队列设计,按时间条件倾向评分匹配PPI起始者与未使用者,随访至死亡或观察结束。
- 使用Cox模型估计风险比(HR)和95%CI,并通过逆概率加权校正信息性删失。
- 共匹配1852对PPI使用者和非使用者,中位生存期2.8年(死亡率26.7/100人年)。
主要发现
- PPI使用与全因死亡风险比HR 1.07(95%CI 0.94-1.22),相对于非使用。
- PPI使用与呼吸相关死亡风险比HR 1.10(95%CI 0.94-1.28)。
- PPI使用与呼吸相关住院风险比HR 1.00(95%CI 0.86-1.16)。
临床怎么用
- 对于IPF患者,不应仅基于既往观察性研究和指南条件性推荐而常规使用PPI以期改善生存或减少住院。
- 临床决策应个体化,权衡PPI的潜在获益与风险,尤其针对有GERD等合并症的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gastroesophageal reflux disease is a common comorbidity in idiopathic pulmonary fibrosis (IPF) and may contribute to its progression. Anti-acid therapy, such as proton pump inhibitors (PPIs), has been considered as a potential treatment option for IPF. The evidence for this treatment comes from several observational studies affected by time-related bias. RESEARCH QUESTION: Is use of PPIs in patients with IPF associated with a reduction in all-cause mortality, respiratory-related mortality, and respiratory-related hospitalization? STUDY DESIGN AND METHODS: We used the UK Clinical Practice Research Datalink to identify a cohort of patients diagnosed with IPF between 2003 and 2016. The prevalent new-user cohort design was used to match patients initiating PPIs with non-users using time-conditional propensity scores, with follow-up until death or end of observation. Cox models were used to estimate hazard ratios (HR) and 95% CIs of death and of a respiratory-related hospitalization, correcting for informative censoring by inverse probability weighting. RESULTS: There were 1,852 PPI users who were matched to 1,852 non-users identified among the cohort of patients with IPF, with a median survival of 2.8 years (mortality rate, 26.7 per 100 per year). The HR of all-cause mortality with PPI use was 1.07 (95% CI, 0.94-1.22), relative to non-use. For respiratory-related mortality, the HR was 1.10 (95% CI, 0.94-1.28) and 1.00 (95% CI, 0.86-1.16) for respiratory-related hospitalizations. INTERPRETATION: PPI use was not associated with lower mortality or hospitalization incidence in this large study conducted among patients with IPF within a real-world setting of clinical practice and designed to avoid the time-related biases affecting previous studies. PPIs may not be as beneficial in treating IPF as suggested by some studies and conditionally recommended in treatment guidelines.
引用
- Tran T, Assayag D, Ernst P, et al. Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis: A Population-Based Cohort Study. Chest. 2020. PMID: 32882251. doi:10.1016/j.chest.2020.08.2080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。